Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Hossmann, S; Tan, S; Mader, JK; Klonoff, DC; Adams, D; Ballhausen, H; Bally, L; Balmer, ML; Braunack-Mayer, V; Bonhoure, A; Burren, D; Boughton, CK; Cengiz, D; Eberle, C; Fabris, C; Friedman, M; Fröhlich-Reiterer, E; Gunn, T; Gusyatiner, O; Hastings, T; Huwiler, VV; Khan-Gallo, S; Levy, CJ; Moser, O; O'Kane, AA; Keighron, C; Oliver, N; Prioleau, T; Thybo, T; Yardley, J; Zueger, T; Faber-Heinemann, G; Heinemann, L; Rothenbühler, M.
One Size Does Not Fit All: The Need for Sex-Specific Precision Medicine in Diabetes Technology.
J Diabetes Sci Technol. 2025; 19322968251340673
Doi: 10.1177/19322968251340673
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Fröhlich-Reiterer Elke
-
Mader Julia
-
Moser Othmar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Incorporating sex-specific factors in diabetes research and treatment is essential for advancing precision medicine. There are critical gaps in understanding and applying sex-related differences. Female-specific diabetes pathophysiology manifests in three major areas: life cycle phases (including puberty, pregnancy, and menopause), lifestyle factors (such as responses to nutrition and physical activity), and insulin pharmacology. These elements significantly affect insulin sensitivity and glycemic control in women, yet are frequently underrepresented or ignored in both research and clinical practice. Greater research and clinical focus across these domains is needed to better understand and address sex-based differences in diabetes. Identifying and filling evidence gaps will support more systematic and effective care.